References
- 1. ARINGER M., COSTENBADER K., DAIKH D., BRINKS R., MOSCA M., RAMSEY-GOLDMAN R., et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–9.
- 2. AL-MOGAIREN SM. Lupus protein-losing enteropathy (LUPLE): a systematic review. Rheumatol Int. 2011;31(8):995–1001.
- 3. TIALMA WA. Ascites, pleural effusion, and CA 125 elevation in an SLE patient, either a Tjalma syndrome or, due to the migrated Filshie clips, a pseudo-Meigs syndrome. Gynecol Oncol. 2005;97(1):288–91.
- 4. HOCHBERG MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
- 5. PETRI M., ORBAI AM., ALARCON GS., GORDON C., MERRILL JT., FORTIN PR., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.
- 6. YOSHIDA M., MIYATA M., SAKA M., SASAJIMA T., SATO H., TAKIGUCHI J., et al. Protein-losing enteropathy exacerbated with the appearance of symptoms of systemic lupus erythematosus. Intern Med. 2001;40(5):449–53.
- 7. CHUNG U., OKA M., NAKAGAWA Y., NISHISHITA T., SEKINE N., TANAKA Y., et al. A patient with protein-losing enteropathy associated with systemic lupus erythematosus. Intern Med. 1992;31(4):521–4.
- 8. WERNER DE CASTRO GR., APPENZRLLER S., BERTOLO MB., COSTALLAT LT. Protein-losing enteropathy associated with systemic lupus erythematosus: response to cyclophosphamide. Rheumatol Int. 2005;25(2):135–8.
- 9. TANSIR G., KUMAR P., PIUS A., SUNNY SK., SONEJA M. Pseudo-pseudo Meigs’ syndrome: a rare presentation of systemic lupus erythematosus. Reumatismo. 2019;71(2):108–12.
- 10. YANG Z., LIANG Y., LI C., ZHONG R. Serum CA125 elevation is independently associated with serositis in SLE patients. Clin Exp Rheumatol. 2012;30(1):93–8.
- 11. ZEIMET AG., MARTH C., OFFNER FA., OBRIST P, UHL-STEIDL M., FEICHTINGER H. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62(3):384–9.
- 12. LI T, XIE QB. A case report of pseudo-pseudo Meigs’ syndrome. Chin Med J (Engl). 2019;132(12):1497–8.
- 13. FAVA A, PETRI M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1–13.
- 14. Health and Labor Sciences Research Grant Subsidy for Intractable Disease Policy Research. Project, Research on autoimmune diseases, Japan college of Rheumatology. Guideline for the management of systemic lupus erythematosus 2019;2019:226-30 (in Japanese)
- 15. FANOURIAKIS A., KOSTOPOULOU M., ALUNNO A., ARINGER M., BAJEMA I., BOLETIS JN. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45.
- 16. HANAOKA H., IIDA H., KIYOKAWA T., TAKAKUWA Y., KAWAHATA K. Hydroxychloroquine improves the disease activity and allows the reduction of the corticosteroid dose regardless of background treatment in Japanese patients with systemic lupus erythematosus. Intern Med. 2019;58(9):1257–62.
- 17. MIYAGAWA I., NAKANO K., NAKAYAMADA S., IWATA S., HANAMI K., FUKUYO S. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. Int J Rheum Dis. 2019;22(3):434–42.